Ira D. Glick, MD; Trisha Suppes, MD, PhD; Charles DeBattista, MD; Rona J. Hu, MD; Stephen Marder, MD
Grant Support: The authors have received financial and/or research funding support from various sources, including the following manufacturers of drugs that may be discussed in this manuscript: Abbott Laboratories, Zeneca, Eli Lilly, Pfizer, Janssen, Novartis, SmithKline Beecham, Parke-Davis, Glaxo Wellcome, Bristol-Meyers Squibb, Forrest Laboratories, Scios, Wyeth-Ayerst, Organon, and Pharmacia Upjohn.
Requests for Single Reprints: Ira D. Glick, MD, Stanford University School of Medicine, 401 Quarry Road, Suite 2122, Stanford, CA 94305-5723; e-mail, email@example.com.
Current Author Addresses: Dr. Glick: Stanford University School of Medicine, 401 Quarry Road, Suite 2122, Stanford, CA 94305-5723.
Dr. Suppes: Bipolar Disorder Clinic, Department of Psychiatry, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9070.
Dr. DeBattista: Stanford University School of Medicine, 401 Quarry Road, Suite 2137, Stanford, CA 94305.
Dr. Hu: Stanford University School of Medicine, 401 Quarry Road, Suite 2114, Stanford, CA 94305.
Dr. Marder: West Los Angeles Veterans Affairs Medical Center, MIRECC 210A, 11301 Wilshire Boulevard, Los Angeles, CA 90072-1003.
Glick ID, Suppes T, DeBattista C, Hu RJ, Marder S. Psychopharmacologic Treatment Strategies for Depression, Bipolar Disorder, and Schizophrenia. Ann Intern Med. 2001;134:47–60. doi: 10.7326/0003-4819-134-1-200101020-00013
Download citation file:
Published: Ann Intern Med. 2001;134(1):47-60.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use